GlassScriptPhysician profile
Jesse Martin Herrman
NPI 1154198562
$2,995.81
in general payments reported to CMS, 2019-2025
18 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $208 · 2024: $1,418 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,988 · Education: $8.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.81 |
| Education | $8.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $770.85 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Vanda Pharmaceuticals INC. | $533.22 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $198.80 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $198.38 | 2024-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $190.63 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $189.88 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $157.70 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $141.22 | 2023-2025 | Ingrezza |
| Indivior INC. | $126.55 | 2023-2025 | Perseris, Sublocade |
| Axsome Therapeutics, INC. | $113.62 | 2024 | Auvelity |
| Lundbeck LLC | $72.80 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $72.43 | 2025 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $60.70 | 2024-2025 | Trintellix |
| Corium, LLC | $47.63 | 2024 | Azstarys |
| Collegium Pharmaceutical, INC. | $42.40 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $34.16 | 2025 | Erzofri Extended-Release |
| Supernus Pharmaceuticals, INC. | $30.66 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $14.18 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Herrman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.